Predictors of BMI reduction with phentermine/topiramate in adolescents with obesity
Authors' conclusion
Baseline characteristics were not predictive of BMI reduction with either dose of PHEN/TPM compared to placebo in adolescents with obesity.
Study context
- Population
- Adolescents aged 12 to <17 years with obesity (BMI ≥95th percentile)final analysis
- Participants
- 222 adolescents
- Comparison
- Mid- or top-dose PHEN/TPM vs placebo
- Primary endpoint
- Association of baseline characteristics (BMI, age, sex, race/ethnicity, pubertal status, diabetes, depression, cognitive function, quality of life) with BMI percent change, PHEN/TPM vs placebo (linear regression)
- Follow-up
- Baseline to 56 weeks
Methodological detailsdouble-blind, placebo-controlled, randomized 1:1:2
- Double-blind
- Placebo-controlled
- Randomized 1:1:2
Primary result
As reported in the abstract
Baseline predictors of BMI % change · 56 weeks
- No baseline characteristic was statistically significantly associated with BMI reduction with mid- or top-dose PHEN/TPM vs placebo
Original publication
Predictors of BMI reduction with phentermine/topiramate in adolescents with obesity. Int J Obes (Lond). Published 15 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →